Brokers Offer Predictions for MDGL Q1 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report issued on Wednesday, November 4th. HC Wainwright analyst A. Ghosh anticipates that the biopharmaceutical company will post earnings of ($0.29) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($7.03) per share. HC Wainwright also issued estimates for Madrigal Pharmaceuticals’ Q2 2027 earnings at $1.60 EPS, Q3 2027 earnings at $3.13 EPS and Q4 2027 earnings at $4.16 EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. The company had revenue of $431.27 million during the quarter, compared to analysts’ expectations of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.93% and a negative net margin of 10.89%. During the same period in the prior year, the business earned ($5.08) earnings per share.

A number of other brokerages also recently weighed in on MDGL. Citigroup increased their price target on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial restated a “buy” rating and set a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Wells Fargo & Company initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Monday, July 27th. They issued an “overweight” rating and a $685.00 target price for the company. Finally, Canaccord Genuity Group increased their target price on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a “buy” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $706.87.

Madrigal Pharmaceuticals Trading Up 1.0%

Shares of MDGL stock opened at $400.43 on Thursday. Madrigal Pharmaceuticals has a 1 year low of $353.54 and a 1 year high of $615.00. The firm’s fifty day simple moving average is $492.40 and its 200 day simple moving average is $498.45. The firm has a market capitalization of $9.25 billion, a P/E ratio of -66.96 and a beta of -0.98. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65.

Insider Buying and Selling

In related news, CEO William Sibold sold 5,221 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $542.39, for a total value of $2,831,818.19. Following the completion of the transaction, the chief executive officer directly owned 197,746 shares of the company’s stock, valued at $107,255,452.94. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of Madrigal Pharmaceuticals stock in a transaction on Monday, August 17th. The stock was sold at an average price of $514.97, for a total transaction of $341,940.08. Following the sale, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. This represents a 5.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 12,247 shares of company stock worth $6,581,182. 17.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. J. Goldman & Co LP acquired a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at about $2,722,000. Royal Bank of Canada increased its stake in Madrigal Pharmaceuticals by 22.5% in the first quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company’s stock valued at $6,557,000 after acquiring an additional 2,303 shares during the period. Hsbc Holdings PLC increased its stake in Madrigal Pharmaceuticals by 1,738.3% in the second quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company’s stock valued at $10,868,000 after acquiring an additional 19,139 shares during the period. Sivik Global Healthcare LLC acquired a new position in Madrigal Pharmaceuticals in the third quarter worth about $1,260,000. Finally, Legal & General Group Plc acquired a new position in Madrigal Pharmaceuticals in the second quarter worth about $6,630,000. Institutional investors own 98.50% of the company’s stock.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results substantially beat expectations. Madrigal reported earnings of $1.83 per share, versus the consensus estimate of a $1.09 loss, and revenue of $431.3 million, ahead of the $404.2 million estimate. Rezdiffra sales growth helped drive the results, with coverage reporting sales surpassed $1 billion. Madrigal Q3 results
• Positive Sentiment: Analysts raised price targets and maintained Buy ratings. Canaccord lifted its target to $633 from $612, Truist to $743 from $709, and Citi to $760 from $725. The upgrades reflect substantial potential upside, though targets are analysts’ estimates, not guarantees. Canaccord rating Truist rating Citi rating
• Neutral Sentiment: Clinical development continues, but key data are not imminent. Madrigal expects the MAESTRO-NASH OUTCOMES readout in late 2027 and is planning a 2,000-plus-patient MAESTRO-CSPH study. These programs offer longer-term potential, but their timelines mean they are less likely to provide a near-term catalyst. Madrigal clinical plans
• Negative Sentiment: Legal investigations and profit-sustainability questions remain risks. Two law firms announced investigations into potential securities-law violations; these are allegations under investigation, not findings of wrongdoing. Separate coverage cited investor concerns about near-term profitability, which could temper the reaction to the strong quarterly beat. Kirby McInerney investigation notice Kaplan Fox investigation notice

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.